fbpx

David Sharek

David Sharek is stock portfolio manager at Shareks Stock Portfolios and the founder of The School of Hard Stocks. Sharek's Growth Stock Portfolio has delivered its investors an average return of 18% per year since inception vs. the S&P 500's 10% during that time (2003-2020). David's delivered five years of +40% returns in his 18 year career, including 106% during 2020. David Sharek's book The School of Hard Stocks can be found on Amazon.com.

Alibaba is Doing Better Than People Think

Alibaba (BABA) was big news after its IPO in 2014. Then the stock went down during 2015 and people lost interest. Today the company is doing better than people think.

Ecolab’s Profits Expected to Accelerate

Ecolab (ECL) expects growth to accelerate during the 2nd half of the year, and with reduced F/X that should help profits grow at double-digit rates.

Becton Dickinson Rallies Ahead of Merger

The merger between Becton Dickinson (BDX) and C.R. Bard is expected to close in the 4th qtr of this year, and BDX stock is rallying ahead of the big event.

Phone to Phone Payments Fueling Fiserv

Phone-to-phone (P2P) payments were up 20% last qtr at Fiserv (FISV), which operates financial software banks utilize to operate their businesses.

Alphabet’s Profit Estimates Lowered — Again

For the second time in the past year Alphabet’s (GOOGL) profit estimates got slashed. GOOGL was expected to make $40 in profits this year, now it’s looking like $30.

Baidu Focused on Artificial Intelligence

Management at Baidu (BIDU) is focused on artificial intelligence, but 86% of company revenue is derived from online ads, so will this company be able to adjust?

S&P 500 Inflows Boost S&P Global

S&P 500 assets soared 38% during the last year, and that’s helped boost shares of S&P Global (SPGI), which makes licensing fees off these investments.

Align Continues its Fabulous Year

Align Technologies (ALGN) is having a fabulous year as its Invisalign clear braces are selling like hotcakes. But ALGN doubled in a year, is it too high to buy?

Amgen Continues to Beat the Street

Amgen (AMGN) continues to beat the street, and could be on its way to its fifth consecutive year of double-digit profit growth. Not bad for a safe stock.

Not a member? Sign up here for $25 a month.